Cargando…

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1

OBJECTIVE: We studied the incidence of dysglycemia and its prediction of the development of type 1 diabetes in islet cell autoantibody (ICA)-positive individuals. In addition, we assessed whether dysglycemia was sustained. RESEARCH DESIGN AND METHODS: Participants (n = 515) in the Diabetes Preventio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosenko, Jay M., Palmer, Jerry P., Rafkin-Mervis, Lisa, Krischer, Jeffrey P., Cuthbertson, David, Mahon, Jeffery, Greenbaum, Carla J., Cowie, Catherine C., Skyler, Jay S.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732147/ https://www.ncbi.nlm.nih.gov/pubmed/19487644 http://dx.doi.org/10.2337/dc08-2140

Ejemplares similares

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2012)

Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High-Risk Population: Receiver operating characteristic analysis
por: Xu, Ping, et al.
Publicado: (2012)

Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2010)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
por: Nathan, Brandon M., et al.
Publicado: (2017)

Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies
por: Yu, Liping, et al.
Publicado: (2012)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
por: Insel, Richard A., et al.
Publicado: (2015)

Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes
por: Lachin, John M., et al.
Publicado: (2011)

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
por: Skyler, Jay S., et al.
Publicado: (2011)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2021)

George S. Eisenbarth: Insulin and Type 1 Diabetes
por: Pugliese, Alberto, et al.
Publicado: (2013)

Neuroanatomical Correlates of Dysglycemia in Young Children With Type 1 Diabetes
por: Marzelli, Matthew J., et al.
Publicado: (2014)

Which comes first in type 1 diabetes: Autoimmunity or dysglycemia?
por: Ikegami, Hiroshi
Publicado: (2023)

The Compelling Case for Anti-CD3 in Type 1 Diabetes
por: Skyler, Jay S.
Publicado: (2013)

Type 1 Diabetes at a Crossroads!
por: Cefalu, William T., et al.
Publicado: (2015)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care 2019;42:2228–2236
por: Sims, Emily K., et al.
Publicado: (2020)

Long-Term Outcome of Individuals Treated With Oral Insulin: Diabetes Prevention Trial–Type 1 (DPT-1) oral insulin trial
por: Vehik, Kendra, et al.
Publicado: (2011)

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
por: Redondo, Maria J., et al.
Publicado: (2018)

Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance
por: Ferrannini, Ele, et al.
Publicado: (2013)

Failure to Preserve β-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New- Onset Type 1 Diabetes
por: Gottlieb, Peter A., et al.
Publicado: (2010)

Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021)

Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes
por: Smith-Palmer, Jayne, et al.
Publicado: (2016)

Performance of HbA(1c) as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth
por: Vehik, Kendra, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_siaosfa1f7po71viac0f75k4h7